Operaciones Annexon, Inc. - ANNX CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Diferencial | 0.06 | ||||||||
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.025457% | ||||||||
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.003235% | ||||||||
Horario tarifa nocturna | 21:00 (UTC) | ||||||||
Cantidad comercializada mínima | 1 | ||||||||
Divisa | USD | ||||||||
Margen | 20% | ||||||||
Mercado de valores | United States of America | ||||||||
Comisión por operación | 0% |
*Information provided by Capital.com
Annexon Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Cierre previo* | 3.11 |
Abrir* | 3.15 |
Cambio de 1 año* | -6.25% |
Rango del día* | 2.98 - 3.2 |
Rango de 52 semanas | 2.07-7.65 |
Volumen medio (10 días) | 2.62M |
Volumen medio (3 meses) | 16.80M |
Capitalización de mercado | 166.15M |
Ratio P/E | -100.00K |
Acciones en circulación | 53.08M |
Ingresos | N/A |
EPS | -2.47 |
Dividendo (Rendimiento %) | N/A |
Beta | -100.00K |
Próxima fecha de resultados | Aug 7, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Cierre | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
Jun 6, 2023 | 3.20 | 0.14 | 4.58% | 3.06 | 3.22 | 2.98 |
Jun 5, 2023 | 3.11 | 0.15 | 5.07% | 2.96 | 3.23 | 2.87 |
Jun 1, 2023 | 3.14 | 0.22 | 7.53% | 2.92 | 3.20 | 2.81 |
May 31, 2023 | 2.97 | 0.14 | 4.95% | 2.83 | 3.03 | 2.60 |
May 30, 2023 | 2.71 | 0.02 | 0.74% | 2.69 | 2.95 | 2.48 |
May 26, 2023 | 2.78 | 0.71 | 34.30% | 2.07 | 2.81 | 2.05 |
May 25, 2023 | 2.06 | -0.36 | -14.88% | 2.42 | 2.44 | 2.04 |
May 24, 2023 | 5.15 | -0.33 | -6.02% | 5.48 | 5.63 | 5.05 |
May 23, 2023 | 5.57 | -0.22 | -3.80% | 5.79 | 6.09 | 5.56 |
May 22, 2023 | 5.94 | 0.27 | 4.76% | 5.67 | 6.04 | 5.66 |
May 19, 2023 | 5.86 | 0.13 | 2.27% | 5.73 | 5.97 | 5.67 |
May 18, 2023 | 5.76 | -0.47 | -7.54% | 6.23 | 6.61 | 5.72 |
May 17, 2023 | 6.35 | 0.38 | 6.37% | 5.97 | 6.40 | 5.78 |
May 16, 2023 | 6.00 | 0.06 | 1.01% | 5.94 | 6.15 | 5.77 |
May 15, 2023 | 6.03 | 0.60 | 11.05% | 5.43 | 6.22 | 5.41 |
May 12, 2023 | 5.44 | -0.02 | -0.37% | 5.46 | 5.59 | 5.41 |
May 11, 2023 | 5.45 | -0.15 | -2.68% | 5.60 | 5.67 | 5.38 |
May 10, 2023 | 5.59 | 0.20 | 3.71% | 5.39 | 5.79 | 5.35 |
May 9, 2023 | 5.43 | 0.33 | 6.47% | 5.10 | 5.48 | 4.90 |
May 8, 2023 | 5.21 | 0.17 | 3.37% | 5.04 | 5.26 | 5.03 |
Annexon, Inc. Events
Hora (UTC) (UTC) | País | Evento |
---|---|---|
Thursday, June 8, 2023 | ||
Hora (UTC) (UTC) 13:30 | País US
| Evento Annexon Inc Annual Shareholders Meeting Annexon Inc Annual Shareholders MeetingForecast -Previous - |
Friday, June 9, 2023 | ||
Hora (UTC) (UTC) 16:00 | País US
| Evento Annexon Inc Annual Shareholders Meeting Annexon Inc Annual Shareholders MeetingForecast -Previous - |
Monday, August 7, 2023 | ||
Hora (UTC) (UTC) 10:59 | País US
| Evento Q2 2023 Annexon Inc Earnings Release Q2 2023 Annexon Inc Earnings ReleaseForecast -Previous - |
Wednesday, November 1, 2023 | ||
Hora (UTC) (UTC) 12:30 | País US
| Evento Q3 2023 Annexon Inc Earnings Release Q3 2023 Annexon Inc Earnings ReleaseForecast -Previous - |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Ingresos totales | 0 | 0 | 0 | 0 | 0 |
Gastos totales de explotación | 145.599 | 130.713 | 63.469 | 32.328 | 19.112 |
Gastos de venta/general/administración Gastos, total | 33.098 | 30.647 | 14.198 | 7.994 | 3.619 |
Investigación y desarrollo | 112.501 | 100.066 | 49.271 | 24.524 | 15.528 |
Ingresos de explotación | -145.599 | -130.713 | -63.469 | -32.328 | -19.112 |
Otros, netos | 3.652 | 0.385 | 0.048 | -4.865 | 0.769 |
Ingresos netos antes de impuestos | -141.947 | -130.323 | -63.412 | -37.179 | -18.303 |
Ingresos netos después de impuestos | -141.947 | -130.323 | -63.412 | -37.183 | -18.304 |
Beneficio neto antes de partidas extra. Elementos | -141.947 | -130.323 | -63.412 | -37.183 | -18.304 |
Total de partidas extraordinarias | |||||
Ingresos netos | -141.947 | -130.323 | -63.412 | -37.183 | -18.304 |
Total Adjustments to Net Income | 0 | -6.924 | -1.095 | -0.176 | |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -141.947 | -130.323 | -70.336 | -38.278 | -18.48 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -141.947 | -130.323 | -70.336 | -38.278 | -18.48 |
Beneficio neto diluido | -141.947 | -130.323 | -70.336 | -38.278 | -18.48 |
Promedio ponderado de acciones diluidas | 54.6736 | 38.3163 | 16.9624 | 187.289 | 187.289 |
BPA diluido sin partidas extraordinarias | -2.59626 | -3.40124 | -4.14658 | -0.20438 | -0.09867 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
BPA normalizado diluido | -2.59626 | -3.40124 | -4.14658 | -0.20504 | -0.09879 |
Gastos (ingresos) extraordinarios | -0.19 | -0.035 | |||
Ingresos por intereses (gastos), netos No operativos | 0.005 | 0.009 | 0.014 | 0.04 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Ingresos totales | 0 | 0 | 0 | 0 | 0 |
Gastos totales de explotación | 41.242 | 36.695 | 36.069 | 37.409 | 35.426 |
Gastos de venta/general/administración Gastos, total | 8.897 | 8.16 | 8.207 | 8.303 | 8.428 |
Investigación y desarrollo | 32.345 | 28.535 | 27.862 | 29.106 | 26.998 |
Ingresos de explotación | -41.242 | -36.695 | -36.069 | -37.409 | -35.426 |
Otros, netos | 2.566 | 2.312 | 1.015 | 0.272 | 0.053 |
Ingresos netos antes de impuestos | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
Ingresos netos después de impuestos | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
Beneficio neto antes de partidas extra. Elementos | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
Ingresos netos | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
Total Adjustments to Net Income | |||||
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
Beneficio neto diluido | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
Promedio ponderado de acciones diluidas | 73.8556 | 72.563 | 68.6529 | 38.5844 | 38.5634 |
BPA diluido sin partidas extraordinarias | -0.52367 | -0.47384 | -0.5106 | -0.96249 | -0.91727 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
BPA normalizado diluido | -0.52367 | -0.47384 | -0.5106 | -0.96249 | -0.91727 |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Activo Corriente | 248.098 | 247.693 | 354.011 | 45.406 | 45.706 |
Efectivo e inversiones a corto plazo | 242.657 | 242.715 | 351.206 | 43.931 | 44.175 |
Efectivo y Equivalentes | 140.02 | 74.843 | 268.565 | 43.931 | 44.175 |
Prepaid Expenses | 5.238 | 4.515 | 2.802 | 1.396 | 1.306 |
Total Assets | 285.096 | 287.04 | 355.946 | 49.898 | 48.149 |
Property/Plant/Equipment, Total - Net | 35.966 | 38.181 | 1.935 | 2.138 | 2.345 |
Property/Plant/Equipment, Total - Gross | 38.849 | 38.97 | 3.906 | 3.442 | 3.156 |
Accumulated Depreciation, Total | -2.883 | -0.789 | -1.971 | -1.304 | -0.811 |
Other Long Term Assets, Total | 1.032 | 1.166 | 0 | 2.354 | 0.098 |
Total Current Liabilities | 22.36 | 21.744 | 10.622 | 4.931 | 3.326 |
Accounts Payable | 7.416 | 11.153 | 3.734 | 2.371 | 1.271 |
Accrued Expenses | 14.764 | 10.452 | 6.497 | 2.194 | 1.713 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.18 | 0.139 | 0.391 | 0.366 | 0.342 |
Total Liabilities | 53.902 | 55.131 | 11.668 | 6.368 | 5.129 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 31.542 | 33.387 | 1.046 | 1.437 | 1.803 |
Total Equity | 231.194 | 231.909 | 344.278 | 43.53 | 43.02 |
Redeemable Preferred Stock | 0 | 0 | 143.984 | 107.222 | |
Common Stock | 0.048 | 0.039 | 0.038 | 0.004 | 0.004 |
Additional Paid-In Capital | 669.78 | 528.365 | 510.309 | 2.202 | 1.257 |
Retained Earnings (Accumulated Deficit) | -438.262 | -296.315 | -165.992 | -102.58 | -65.397 |
Other Equity, Total | -0.372 | -0.18 | -0.077 | -0.08 | -0.066 |
Total Liabilities & Shareholders’ Equity | 285.096 | 287.04 | 355.946 | 49.898 | 48.149 |
Total Common Shares Outstanding | 47.723 | 38.5608 | 38.1576 | 187.289 | 187.289 |
Total deudores, neto | 0 | 0.003 | 0.079 | 0.225 | |
Inversiones a corto plazo | 102.637 | 167.872 | 82.641 | ||
Other Current Assets, Total | 0.203 | 0.463 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Activo Corriente | 232.536 | 248.098 | 274.777 | 181.372 | 211.254 |
Efectivo e inversiones a corto plazo | 228.165 | 242.657 | 269.519 | 177.594 | 206.659 |
Efectivo y Equivalentes | 144.12 | 140.02 | 210.658 | 104.614 | 112.828 |
Inversiones a corto plazo | 84.045 | 102.637 | 58.861 | 72.98 | 93.831 |
Total deudores, neto | |||||
Prepaid Expenses | 4.206 | 5.238 | 5.201 | 3.741 | 4.461 |
Total Assets | 268.778 | 285.096 | 312.722 | 220.704 | 250.569 |
Property/Plant/Equipment, Total - Net | 35.198 | 35.966 | 36.709 | 37.282 | 37.908 |
Accumulated Depreciation, Total | -3.419 | -2.883 | -2.353 | -1.834 | -1.295 |
Other Long Term Assets, Total | 1.044 | 1.032 | 1.236 | 2.05 | 1.407 |
Total Current Liabilities | 22.941 | 22.36 | 20.22 | 20.254 | 17.053 |
Accounts Payable | 10.346 | 7.416 | 6.921 | 10.301 | 9.378 |
Accrued Expenses | 12.211 | 14.764 | 13.129 | 9.789 | 7.486 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.384 | 0.18 | 0.17 | 0.164 | 0.189 |
Total Liabilities | 53.917 | 53.902 | 52.12 | 52.66 | 49.955 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 30.976 | 31.542 | 31.9 | 32.406 | 32.902 |
Total Equity | 214.861 | 231.194 | 260.602 | 168.044 | 200.614 |
Common Stock | 0.053 | 0.048 | 0.048 | 0.039 | 0.039 |
Additional Paid-In Capital | 691.963 | 669.78 | 664.839 | 537.269 | 532.636 |
Retained Earnings (Accumulated Deficit) | -476.938 | -438.262 | -403.879 | -368.825 | -331.688 |
Other Equity, Total | -0.217 | -0.372 | -0.406 | -0.439 | -0.373 |
Total Liabilities & Shareholders’ Equity | 268.778 | 285.096 | 312.722 | 220.704 | 250.569 |
Total Common Shares Outstanding | 53.0807 | 47.723 | 47.6265 | 38.6039 | 38.5636 |
Property/Plant/Equipment, Total - Gross | 38.617 | 38.849 | 39.062 | 39.116 | 39.203 |
Other Current Assets, Total | 0.165 | 0.203 | 0.057 | 0.037 | 0.134 |
Redeemable Preferred Stock |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Ingresos netos/Línea de salida | -141.947 | -130.323 | -63.412 | -37.183 | -18.304 |
Efectivo de actividades de explotación | -116.309 | -106.11 | -53.087 | -28.358 | -17.19 |
Efectivo de actividades de explotación | 2.106 | 2.141 | 0.667 | 0.493 | 0.488 |
Partidas no monetarias | 19.794 | 18.788 | 4.941 | 7.707 | 0.148 |
Cash Taxes Paid | 0 | 0.002 | 0.001 | ||
Cambios en el capital circulante | 3.738 | 3.284 | 4.717 | 0.625 | 0.478 |
Efectivo de actividades de inversión | 58.443 | -88.236 | -83.164 | -0.267 | -0.017 |
Gastos de capital | -6.526 | -1.654 | -0.464 | -0.267 | -0.017 |
Efectivo procedente de actividades de financiación | 122.908 | 1.795 | 360.876 | 28.395 | 58.456 |
Emisión (retiro) de acciones, neto | 130.896 | 1.795 | 363.85 | 30 | 58.456 |
Efectos del cambio de divisas | 0.001 | -0.005 | 0.009 | -0.014 | -0.04 |
Variación neta de la tesorería | 65.043 | -192.556 | 224.634 | -0.244 | 41.209 |
Elementos de flujo de caja de financiación | -7.988 | 0 | -2.974 | -1.605 | 0 |
Otras partidas de flujo de caja de inversión, total | 64.969 | -86.582 | -82.7 | ||
Emisión (amortización) de deuda, neta | 0 | 0 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -38.676 | -141.947 | -107.564 | -72.51 | -35.373 |
Cash From Operating Activities | -32.993 | -116.309 | -89.17 | -58.452 | -30.288 |
Cash From Operating Activities | 0.536 | 2.106 | 1.576 | 1.058 | 0.518 |
Non-Cash Items | 3.969 | 19.794 | 14.89 | 9.842 | 4.862 |
Changes in Working Capital | 1.178 | 3.738 | 1.928 | 3.158 | -0.295 |
Cash From Investing Activities | 19.517 | 58.443 | 102.058 | 87.96 | 68.251 |
Capital Expenditures | -0.137 | -6.526 | -6.244 | -6.075 | -5.214 |
Other Investing Cash Flow Items, Total | 19.654 | 64.969 | 108.302 | 94.035 | 73.465 |
Cash From Financing Activities | 17.581 | 122.908 | 122.8 | 0.132 | 0.019 |
Financing Cash Flow Items | -7.988 | -7.853 | |||
Issuance (Retirement) of Stock, Net | 17.581 | 130.896 | 130.653 | 0.132 | 0.019 |
Foreign Exchange Effects | -0.005 | 0.001 | -0.007 | -0.003 | 0.003 |
Net Change in Cash | 4.1 | 65.043 | 135.681 | 29.637 | 37.985 |
Issuance (Retirement) of Debt, Net |
Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
---|---|---|---|---|---|---|
Satter Management Co., L.P. | Private Equity | 13.2922 | 7056024 | 0 | 2023-03-31 | MED |
Bain Capital Life Sciences Investors, LLC | Investment Advisor | 10.7413 | 5701926 | 815310 | 2023-05-25 | LOW |
Adage Capital Management, L.P. | Hedge Fund | 6.6875 | 3549975 | 0 | 2023-03-31 | MED |
Redmile Group, LLC | Investment Advisor/Hedge Fund | 6.5993 | 3503190 | 0 | 2023-03-31 | LOW |
VR Adviser, LLC | Venture Capital | 6.066 | 3220050 | 0 | 2023-03-31 | MED |
Federated Hermes Global Investment Management Corp. | Investment Advisor/Hedge Fund | 5.7603 | 3057800 | 0 | 2023-03-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 4.5459 | 2413117 | -87190 | 2023-03-31 | HIGH |
Eventide Asset Management, LLC | Investment Advisor | 3.5175 | 1867250 | -1759258 | 2023-03-31 | MED |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.9575 | 1569971 | 21100 | 2023-03-31 | LOW |
GMT Capital Corp. | Hedge Fund | 2.6537 | 1408697 | 1408697 | 2023-03-31 | LOW |
Millennium Management LLC | Hedge Fund | 2.5702 | 1364343 | 837812 | 2023-03-31 | HIGH |
Cormorant Asset Management, LP | Hedge Fund | 2.3548 | 1250000 | 1250000 | 2023-03-31 | LOW |
Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 2.3222 | 1232713 | 0 | 2023-03-31 | LOW |
Octagon Capital Advisors LP | Hedge Fund | 2.2417 | 1190000 | 1190000 | 2023-03-31 | MED |
Driehaus Capital Management, LLC | Investment Advisor/Hedge Fund | 2.0552 | 1090986 | -200586 | 2023-03-31 | HIGH |
Invus Public Equities Advisors, LLC | Investment Advisor | 1.9183 | 1018303 | 1018303 | 2023-03-31 | LOW |
Polar Capital LLP | Investment Advisor/Hedge Fund | 1.8838 | 1000000 | 1000000 | 2023-03-31 | LOW |
Soleus Capital Management, L.P. | Hedge Fund | 1.7244 | 915400 | 915400 | 2023-03-31 | HIGH |
Novartis AG | Corporation | 1.7157 | 910747 | -1196497 | 2021-12-31 | LOW |
Clarus Ventures, LLC | Venture Capital | 1.7147 | 910211 | 0 | 2023-03-31 | MED |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group535K+
Traders
87K+
Clientes activos mensualmente
$113M+
Volumen mensual de inversión
$64M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Annexon, Inc. Company profile
Sobre Annexon Inc
Annexon, Inc. es una empresa biofarmacéutica en fase clínica que está desarrollando una línea de terapias para pacientes con trastornos clásicos del cuerpo, el cerebro y los ojos mediados por el complemento. El producto candidato de la empresa, ANX005, es un anticuerpo monoclonal de longitud completa formulado para su administración intravenosa en trastornos autoinmunes y neurodegenerativos. Su producto candidato, ANX007, es un fragmento de unión a antígeno (Fab), formulado para la administración intravítrea para el tratamiento de trastornos oftálmicos neurodegenerativos. También está desarrollando ANX009, que es una formulación subcutánea en investigación de un Fab diseñado para el tratamiento de enfermedades autoinmunes sistémicas. Ha completado los ensayos clínicos de fase 1b de seguridad y de rango de dosis para ANX005 y ANX007 en pacientes con síndrome de Guillain-Barré (SGB) y glaucoma, respectivamente. También está realizando ensayos clínicos en múltiples enfermedades autoinmunes, neurodegenerativas y oftálmicas graves.
El precio actual de la acción Annexon, Inc. en tiempo real es 3.19 USD. El gráfico de la acción permite a los inversores comprender mejor el rendimiento y el precio de la acción y tomar decisiones informadas al negociar acciones y CFD.
Descubra más acciones con gráficos, datos vitales y actualizaciones de precios en tiempo real: iRobot Corporation, Columbus McKinnon, Konica Minolta, Inc., Turning Point Therapeutics, Inc., Kerry Properties Limited y Temple Bar Investment Trust PLC. Para obtener más información, consulte los perfiles de las empresas en Capital.com.
Industry: | Biopharmaceuticals |
1400 Sierra Point Parkway
Bldg C Suite 200
BRISBANE
CALIFORNIA 94005
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 535.000 traders de todo el mundo que eligen operar con Capital.com